- Medical Device Leaders Shlomi Nachman and
Timothy Scannell to join Board of
Directors
BOSTON, July 16,
2024 /PRNewswire/ -- CereVasc, Inc., a
clinical-stage, medical device company developing novel treatments
for neurological diseases, today announced the following
appointments to the Company's Board of Directors, effective
July 11, 2024:
- Shlomi Nachman, former Company
Group Chairman of Cardiovascular and Specialty Solutions and Vision
Groups within Johnson & Johnson's Medical Devices sector
- Timothy Scannell, former
President and Chief Operating Officer of Stryker
"We are excited to welcome Shlomi and Tim to the CereVasc
Board," said Dan Levangie, Chairman
and CEO. "They both bring a wealth of experience in the medical
device and neurovascular fields and have distinguished careers in
leading prominent medical device organizations. We look forward to
leveraging their expertise and insights to bring the eShunt System
to the market."
Mr. Nachman has over 25 years of experience in the medical
device industry and is currently on the board of several medical
device companies, as well as the Arnold and Mable Beckman
Foundation, a foundation focused on supporting research in
chemistry and life sciences. Previously, he held senior operating
roles at Johnson & Johnson, where he was the Company Group
Chairman of Cardiovascular and Specialty Solutions and Vision
Groups within Johnson & Johnson's Medical Devices sector. Prior
to that, Mr. Nachman had various roles with increased scope and
responsibilities including Worldwide President of Biosense Webster
and Cordis. He earned his Bachelor of Science in Management
& Economics from the Israel Institute of Technology and a
Diploma in Electrical Engineering from the Amal Technical
School.
Mr. Scannell brings over 30 years of experience and success
delivering market-leading results from his leadership roles at
Stryker Corporation, one of the world's leading medical technology
companies. Mr. Scannell served as President and Chief Operating
Officer of Stryker between 2018 and 2021, overseeing all of
Stryker's commercial businesses and regions globally. Prior to
this, he served as group president for Stryker's MedSurg &
Neurotechnology businesses for ten years. Mr. Scannell currently
serves as a director and non-executive chairman of the Board of
Directors for Insulet Corporation (Nasdaq: PODD) and is a director
on the boards of Novocure (Nasdaq: NVCR), Synaptive Medical,
Regenity Biosciences, and Molekule. Mr. Scannell holds a Bachelor
of Business Administration and a Master of Business Administration
from the University of Notre Dame.
About CereVasc, Inc.
Located
in Massachusetts' healthcare hub, CereVasc, Inc., is a
clinical stage, medical device company focused on the development
of novel, minimally invasive treatments for patients with
neurological diseases. Its initial product, the eShunt System,
encompasses first-ever, groundbreaking percutaneous
transvenous-transdural access to the central nervous system
intended to allow the first minimally invasive treatment for
communicating hydrocephalus (CH), a potential improvement to the
current standard of care. The eShunt device concept originated from
Tufts Medical Center physicians Carl Heilman, MD,
Neurosurgeon-in-Chief and Chair of Neurosurgery, and Adel
Malek, MD, PhD, Chief of Neurovascular Surgery and Director of
Endovascular Neurosurgery. The patented eShunt System includes an
endovascularly implantable cerebral spinal fluid shunt
and delivery components, which are designed to treat CH
without invasive surgery. For additional information, please visit
our website at www.cerevasc.com.
The eShunt® Device is an investigational device and
not available for sale within or outside the United States.
Company Contacts:
DJ Cass
CereVasc, Inc.
djcass@cerevasc.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cerevasc-announces-appointments-of-new-directors-302197715.html
SOURCE CereVasc